Chemiluminescent FemtoMax™ Super Sensitive HRP Substrate
29 References
FEMTOMAX-020
FEMTOMAX-110
20 mL
110 mL
Liquid - clear, colorless, odorless
Liquid - clear, colorless, odorless
WB, ELISA
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Chemiluminescent FemtoMax™ Super Sensitive HRP Substrate for Microwell and/or Membrane (2 component system) - FEMTOMAX-020
Peroxidase Substrate, ECL HRP Substrate, Chemiluminescent Femtomax™ Super Sensitive horseradish peroxidase (HRP) Substrate For Microwell And/Or Membrane (2 Component System)
Application Details
WB
ELISA
- View References
Prepare FemtoMax™ Super Sensitive Chemiluminescent HRP Substrate for use in microwell or membrane applications by mixing 1 mL of Luminol Reagent (Reagent A) with 1 mL of Reaction Buffer (Reagent B). Mix well. Protect from light. Larger or smaller volumes of the substrate can be prepared by mixing components at the same 1:1 ratio. FemtoMax™ Super Sensitive Chemiluminescent HRP Substrate is a highly sensitive detection reagent. Always carefully optimize all components of individual assays (antigens, antibodies, conjugates…) to minimize background reactivity associated with non-specific binding.
Shipping & Handling
Wet Ice
Store container at 4° C prior to opening. Protect from moisture and light. No special shipping conditions or precautions are required.
FemtoMax™ Super Sensitive Chemiluminescent HRP Substrate is an extremely sensitive, nonradioactive, enhanced luminol-based chemiluminescent substrate for the detection of horseradish peroxidase (HRP). FemtoMax™ is designed for both Western blotting and enzyme-linked immunosorbent assay (ELISA) use. FemtoMax™ easily allows for the detection of femtogram (10-15) amounts of antigen using photographic film or other imaging methods, including highly sensitive CCD cameras. Blots can be repeatedly exposed to X-ray film to obtain optimal results or stripped of detection reagents and re-probed. Use the same blotting conditions for FemtoMax™ as you would when using Amersham ECL Plus™ Substrate or Pierce SuperSignal® West Femto Substrate.
Teske NC et al. (2023). Pericytes are protective in experimental pneumococcal meningitis through regulating leukocyte infiltration and blood-brain barrier function. J Neuroinflammation.
Applications
Protein Assay
Chithelen J et al. (2022). The Sphingolipid Inhibitors Ceranib-2 and SKI-II Reduce Measles Virus Replication in Primary Human Lymphocytes: Effects on mTORC1 Downstream Signaling. Front Physiol.
Applications
WB, IB, PCA
Mollin M et al. (2021). Clinical, functional and genetic characterization of 16 patients suffering from chronic granulomatous disease variants – identification of 11 novel mutations in CYBB. Clin Exp Immunol.
Applications
WB, IB, PCA
Bakri FG et al. (2021). Second Report of Chronic Granulomatous Disease in Jordan: Clinical and Genetic Description of 31 Patients From 21 Different Families, Including Families From Lybia and Iraq. Front Immunol.
Applications
WB, IB, PCA
Pyun JM et al. (2021). Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity. Clinical Interventions in Aging
Applications
E, EIA
Kim MK et al. (2021). A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression. Biomed Pharmacother.
Applications
WB, IB, PCA
Zhang L et al. (2020). Functional analysis of miR-767-5p during the progression of hepatocellular carcinoma and the clinical relevance of its dysregulation. Histochem Cell Biol.
Applications
WB, IB, PCA
Nguyen J et al. (2020). A Synthetic Peptide, CK2. 3, Inhibits RANKL-Induced Osteoclastogenesis through BMPRIa and ERK Signaling Pathway. J Dev Biol.
Applications
WB, IB, PCA
Durbano HW et al. (2020). Aberrant BMP2 Signaling in Patients Diagnosed with Osteoporosis. Int J Mol Sci.
Applications
WB, IB, PCA
Youn YC. et al. (2020). Blood Amyloid-β Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study. J Alzheimers Dis.
Applications
WB, IB, PCA
Brault J. et al. (2020). NOX4 is the main NADPH oxidase involved in the early stages of hematopoietic differentiation from human induced pluripotent stem cells. Free Radic Biol Med.
Applications
WB, IB, PCA
Lee JJ et al. (2020). Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer's Disease in Health Screening Population. Diagnostics (Basel, Switzerland)
Applications
E, EIA
Grafen A et al. (2019). Use of acid ceramidase and sphingosine kinase inhibitors as antiviral compounds against measles virus infection of lymphocytes in vitro. Front Cell Dev Biol
Applications
WB, IB, PCA
John V et al. (2019). Caveolin-1 controls vesicular TLR2 expression, p38 signaling and T cell suppression in BCG infected murine monocytic myeloid-derived suppressor cells. Front Immunol.
Applications
WB, IB, PCA
Chung et al. (2018). Niche-mediated BMP/SMAD signaling regulates lung alveolar stem cell proliferation and differentiation. Development
Applications
WB, IB, PCA
Kim TH et al. (2018). Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice. Eur J Pharmacol.
Applications
WB, IB, PCA
Tiwarekar V et al. (2018). APOBEC3G-regulated host factors interfere with measles virus replication: role of REDD1 and mammalian TORC1 inhibition. J Virol.
Applications
WB, IB, PCA
Dietrich K et al. (2018). Health-Relevant Phenotypes in the Offspring of Mice Given CAR Activators Prior to Pregnancy. Drug Metab Dispos.
Applications
WB, IB, PCA
Barfeld SJ et al. (2017). c-Myc antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks. EBioMedicine.
Applications
WB, IB, PCA
An SSA et al. (2017). Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42. Alzheimer's Research & Therapy
Applications
E, EIA
Wang MJ et al. (2017). Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Alzheimer's Research & Therapy
Applications
E, EIA
Tadokoro T et al. (2016). BMP signaling and cellular dynamics during regeneration of airway epithelium from basal progenitors. Development.
Applications
WB, IB, PCA
Wache C et al. (2015). Myeloid-related protein 14 promotes inflammation and injury in meningitis. J Infect Dis.
Applications
WB, IB, PCA
Carter LG et al. (2015). Exercise improves glucose disposal and insulin signaling in pregnant mice fed a high fat diet. J Diabetes Metab.
Applications
WB, IB, PCA
Beaumel S et al. (2014). Identification of NOX2 regions for normal biosynthesis of cytochrome b558 in phagocytes highlighting essential residues for p22phox binding. Biochem J.
Applications
WB, IB, PCA
Hohne C et al. (2013). High mobility group box 1 prolongs inflammation and worsens disease in pneumococcal meningitis. Brain.
Applications
WB, IB, PCA
Huang BW et al. (2013). Transcriptional regulation of the human ferritin gene by coordinated regulation of Nrf2 and protein arginine methyltransferases PRMT1 and PRMT4. FASEB J.
Applications
WB, IB, PCA
Kim MK et al. (2013). Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses. PLoS One.
Applications
WB, IB, PCA
Hoegen T et al. (2011). The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATP-dependent lysosomal cathepsin B release. J Immunol.
Applications
WB, IB, PCA
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.